First Quarter 2021 Highlights
Revenue of $1.2 billion, a decrease of 4 percent versus Q1 2020 and down 5 percent organically
1
Adjusted EBITDA of $307 million, down 14 percent versus Q1 2020
Consolidated GAAP earnings of $1.40 per diluted share, down 11 percent versus Q1 2020
Consolidated adjusted earnings per diluted share of $1.53, down 17 percent versus Q1 2020
Share repurchases of $75 million
Full-Year Outlook
2
Maintains revenue forecast in the range of $4.9 to $5.1 billion, reflecting 8 percent growth at the midpoint versus 2020
Maintains adjusted EBITDA forecast in the range of $1.32 to $1.42 billion, reflecting 10 percent growth at the midpoint versus 2020
Raises 2021 adjusted earnings forecast to a range of $6.70 to $7.40 per diluted share, reflecting 14 percent growth at the midpoint versus 2020, excluding any impact from future share repurchases
FMC Corporation announces executive leadership change in EMEA region
USA - English
Share this article
PHILADELPHIA, April 15, 2021 /PRNewswire/
FMC Corporation (NYSE: FMC), a leading global agricultural sciences company, today announced Marc Hullebroeck, FMC vice president and president of the Europe, Middle East and Africa (EMEA) region, will retire from the company at the end of June 2021. He will be succeeded by Sebastia Pons, currently director of Portfolio Strategy and Strategic Marketing in the EMEA region.
Hullebroeck will retire following a 31-year career with FMC, and a total of more than 40 years in the agricultural industry. Throughout most of his career, he led the company s commercial organizations in Asia Pacific, EMEA, Latin America and North America. Since 2013, Hullebroeck has had executive oversight for the company s Plant Health business and third-party engagements in addition to his regional responsibilities, and in 2016 he established FMC s Europ
Tebuconazole Market Size Estimated to Reach $925 Million by 2025 Increase Demand for Food Crops, Cereals and Vegetables and Usage of Fungicides for the Development of Crops Is Driving the Usage of Tebuconazole in Crop Pesticide Segments During the Forecast Period.
BriefingWire.com, 3/16/2021 - Tebuconazole Market size is estimated to reach $ 925 Million by 2025, growing at a CAGR of 4.7% during the forecast period 2020-2025. Tebuconazole is a triazole fungicide that is used to treat the pathogenic fungi in the plants. Tebuconazole is also used as a raw material in the seed coating. Tebuconazole helps in a wide variety of farming activities for the treatment and protection of the crops. An increase in the global population and an increase in demand for fruits, vegetables and cereals are increasing the usage of the tebuconazole in agriculture for getting high yield to reach the need for crops is driving the market during the forecast period 2020-2025.
2021 Corporate Partners
Thank you to our 2021 ESA Corporate Partners! Funds generated from this program help support ESA s programming, thus supporting members work and professional development. Please show your support of these businesses throughout the year when possible. Visit the ESA Corporate Partners Program Page to learn more about becoming a Corporate Partner.
Corteva Agriscience™ brings together DuPont Crop Protection, DuPont Pioneer and Dow AgroSciences to create a market-shaping, standalone agriculture company with leading positions in seed technologies, crop protection and digital agriculture. We will work across the global agriculture value chain to create a more efficient food system. At Corteva Agriscience™, we seek to enrich the lives of those who produce and those who consume. This means we will help rejuvenate the agricultural ecosystem to support people and the planet and to ensure progress for generations to come.
Fourth Quarter 2020 Highlights
1
Adjusted EBITDA of $290 million, down 9 percent versus Q4 2019
GAAP earnings of $0.38 per diluted share, versus a loss of $0.02 per diluted share in Q4 2019
Adjusted earnings per diluted share of $1.42, down 19 percent versus Q4 2019
Full-Year 2020 Highlights
1
Adjusted EBITDA of $1.25 billion, up 2 percent versus 2019
GAAP earnings of $4.22 per diluted share, up 17 percent versus 2019
Adjusted earnings per diluted share of $6.19, up 2 percent versus 2019
GAAP cash flow from operations of $737 million, up 33 percent versus 2019
Free cash flow of $544 million, up 80 percent versus 2019
Full-Year 2021 Outlook
2
Revenue in the range of $4.9 to $5.1 billion, reflecting 8 percent growth at the midpoint versus 2020
Adjusted EBITDA in the range of $1.32 to $1.42 billion, reflecting 10 percent growth at the midpoint versus 2020